Literature DB >> 8898811

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects.

H Miettinen1, S M Haffner, S Lehto, T Rönnemaa, K Pyörälä, M Laakso.   

Abstract

BACKGROUND AND
PURPOSE: Increased urinary albumin and protein excretion is associated with cardiovascular disease mortality independent of other cardiovascular risk factors in subjects with non-insulin-dependent diabetes mellitus (NIDDM). We assessed the relationship between the different degrees of proteinuria at baseline and the incidence of stroke, as well as other atherosclerotic vascular disease events, in a prospective study of nondiabetic and NIDDM subjects.
METHODS: Our study was based on the 7-year follow-up of cohorts of nondiabetic (n = 1375) and NIDDM (n = 1056) subjects in Finland. The urinary protein concentration at baseline was stratified into three categories: no proteinuria (< 150 mg/L), borderline (150 to 300 mg/L), and clinical proteinuria (> 300 mg/L).
RESULTS: The association between the different degrees of proteinuria and the atherosclerotic vascular events was similar in nondiabetic and NIDDM subjects. Cardiovascular disease mortality was higher both in nondiabetic and NIDDM subjects with clinical proteinuria than in those without proteinuria. The incidence of stroke was 1.6% in nondiabetic subjects without proteinuria, 3.2% in subjects with borderline proteinuria, and 8.5% in subjects with clinical proteinuria (P < .001 for trend). In NIDDM patients, the corresponding rates were 7.2%, 11.1%, and 23.0%, respectively (P < .001 for trend). The association between clinical proteinuria and the incidence of stroke remained significant both in nondiabetic and in NIDDM subjects after adjustment for other cardiovascular risk factors. Clinical proteinuria was also associated with the incidence of coronary heart disease events and that of lower-extremity amputation. NIDDM independently increased the risk of atherosclerotic vascular disease events regardless of the proteinuria status.
CONCLUSIONS: Clinical proteinuria significantly predicted stroke and other atherosclerotic vascular disease events independent of other cardiovascular risk factors. This finding is compatible with the view that increased urinary protein excretion rate may be associated with widespread vascular damage.

Entities:  

Mesh:

Year:  1996        PMID: 8898811     DOI: 10.1161/01.str.27.11.2033

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  41 in total

1.  An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study.

Authors:  A Y T Wu; N C T Kong; F A de Leon; C Y Pan; T Y Tai; V T F Yeung; S J Yoo; A Rouillon; M R Weir
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

2.  Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women.

Authors:  A Juutilainen; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Diabetologia       Date:  2005-12-20       Impact factor: 10.122

Review 3.  Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II.

Authors:  Ravi Nistala; Adam Whaley-Connell
Journal:  Mol Cell Endocrinol       Date:  2013-02-15       Impact factor: 4.102

4.  Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes.

Authors:  Elizabeth F O Kern; Miriam Maney; Donald R Miller; Chin-Lin Tseng; Anjali Tiwari; Mangala Rajan; David Aron; Leonard Pogach
Journal:  Health Serv Res       Date:  2006-04       Impact factor: 3.402

5.  Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes.

Authors:  Meda E Pavkov; Peter H Bennett; Maurice L Sievers; Jonathan Krakoff; Desmond E Williams; William C Knowler; Robert G Nelson
Journal:  Kidney Int       Date:  2005-09       Impact factor: 10.612

6.  Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Authors:  Frank Weidemann; Johannes Krämer; Thomas Duning; Malte Lenders; Sima Canaan-Kühl; Alice Krebs; Hans Guerrero González; Claudia Sommer; Nurcan Üçeyler; Markus Niemann; Stefan Störk; Michael Schelleckes; Stefanie Reiermann; Jörg Stypmann; Stefan-Martin Brand; Christoph Wanner; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2014-02-20       Impact factor: 10.121

7.  Prevalence and risk factors of albuminuria in Type 2 diabetes in Bahrain.

Authors:  R A Al-Salman; H A Al-Basri; A S Al-Sayyad; H M Hearnshaw
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

8.  Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA).

Authors:  K Wattanakit; A R Folsom; M H Criqui; H J Kramer; M Cushman; S Shea; A T Hirsch
Journal:  Atherosclerosis       Date:  2008-02-20       Impact factor: 5.162

Review 9.  Cardiovascular implications of proteinuria: an indicator of chronic kidney disease.

Authors:  Varun Agrawal; Victor Marinescu; Mohit Agarwal; Peter A McCullough
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

Review 10.  Update on the use of trandolapril in the management of cardiovascular disorders.

Authors:  Ariel Diaz; Anique Ducharme
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.